BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic
BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic diseases through aging biology, has announced its participation in the Goldman Sachs Second Annual "Year-Ahead" Catalyst Clinic. The presentation is scheduled for Thursday, December 19, 2024, from 11-12 PM EST.
The event will feature a virtual presentation that will be accessible via webcast. Interested parties can access the live presentation through registration, and replays will be available on the company's investor relations website for 30 days following the event.
BioAge Labs (Nasdaq: BIOA), un'azienda biofarmaceutica in fase clinica che si concentra sullo sviluppo di terapie per malattie metaboliche attraverso la biologia dell'invecchiamento, ha annunciato la sua partecipazione al Goldman Sachs Second Annual "Year-Ahead" Catalyst Clinic. La presentazione è programmata per giovedì 19 dicembre 2024, dalle 11 alle 12 PM EST.
L'evento prevede una presentazione virtuale che sarà accessibile tramite webcast. Le parti interessate possono accedere alla presentazione in diretta registrandosi, e le registrazioni saranno disponibili sul sito web delle relazioni con gli investitori dell'azienda per 30 giorni dopo l'evento.
BioAge Labs (Nasdaq: BIOA), una empresa biofarmacéutica en etapa clínica centrada en desarrollar terapias para enfermedades metabólicas a través de la biología del envejecimiento, ha anunciado su participación en el Goldman Sachs Second Annual "Year-Ahead" Catalyst Clinic. La presentación está programada para el jueves 19 de diciembre de 2024, de 11 a 12 PM EST.
El evento contará con una presentación virtual que será accesible a través de un webcast. Las partes interesadas pueden acceder a la presentación en vivo mediante registro, y las repeticiones estarán disponibles en el sitio web de relaciones con inversores de la empresa durante 30 días después del evento.
BioAge Labs (Nasdaq: BIOA)는 노화 생물학을 통해 대사 질환에 대한 치료제를 개발하는 데 중점을 둔 임상 단계의 생명공학 회사로, Goldman Sachs Second Annual "Year-Ahead" Catalyst Clinic에 참여한다고 발표했습니다. 발표는 2024년 12월 19일 목요일 오전 11시부터 오후 12시(EST)까지 예정되어 있습니다.
이 행사는 웹캐스트를 통해 접근 가능한 가상 발표로 진행됩니다. 관심 있는 개인은 등록을 통해 실시간 발표에 접근할 수 있으며, 행사가 끝난 후 30일 동안 회사의 투자자 관계 웹사이트에서 재생이 가능합니다.
BioAge Labs (Nasdaq: BIOA), une entreprise biopharmaceutique en phase clinique se concentrant sur le développement de thérapies pour les maladies métaboliques à travers la biologie du vieillissement, a annoncé sa participation au Goldman Sachs Second Annual "Year-Ahead" Catalyst Clinic. La présentation est prévue pour le jeudi 19 décembre 2024, de 11h à 12h EST.
L'événement comprendra une présentation virtuelle qui sera accessible via un webcast. Les parties intéressées peuvent accéder à la présentation en direct par enregistrement, et les rediffusions seront disponibles sur le site web des relations investisseurs de l'entreprise pendant 30 jours après l'événement.
BioAge Labs (Nasdaq: BIOA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für Stoffwechselerkrankungen durch Alterungsbiologie konzentriert, hat seine Teilnahme an der Goldman Sachs Second Annual "Year-Ahead" Catalyst Clinic bekannt gegeben. Die Präsentation ist für Donnerstag, den 19. Dezember 2024, von 11 bis 12 Uhr EST geplant.
Die Veranstaltung wird eine virtuelle Präsentation umfassen, die über einen Webcast zugänglich ist. Interessierte Parteien können sich registrieren, um auf die Live-Präsentation zuzugreifen, und Aufzeichnungen werden 30 Tage nach der Veranstaltung auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Goldman Sachs Second Annual “Year-Ahead” Catalyst Clinic on Thursday, December 19, 2024, 11–12 PM EST.
To access the live webcast of the virtual presentation, register here. Replays of the webcast will be available in the investor section of the Company’s website at https://ir.bioagelabs.com, and will be archived for 30 days following the presentation.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead product candidate, azelaprag, is an orally available small molecule agonist of APJ that was observed to promote metabolism and prevent muscle atrophy on bed rest in a Phase 1b clinical trial. In mid-2024, BioAge initiated a Phase 2 trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. BioAge’s preclinical programs, based on novel insights from the company’s discovery platform built on human longevity data, address key pathways in metabolic aging.
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Elena Liapounova, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com
FAQ
When is BioAge Labs (BIOA) presenting at the Goldman Sachs Catalyst Clinic 2024?
How can investors access BioAge Labs' (BIOA) Goldman Sachs presentation?
What is the focus of BioAge Labs' (BIOA) therapeutic development?
